(CGEM) Cullinan Oncology - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 838m USD | Total Return: 96% in 12m
Avg Turnover: 17.2M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Choppy
Tailwinds
Rs Leader, Confidence, Tailwind, Pullback 52w
Cullinan Therapeutics (NASDAQ: CGEM) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for autoimmune diseases and oncology. Its pipeline features several bispecific T cell engagers, including CLN-978 and Velinotamig, alongside Zipalertinib, an oral small-molecule inhibitor currently in Phase 2b trials for non-small cell lung cancer. The company utilizes a hub-and-spoke business model, establishing strategic partnerships with entities like Taiho Pharmaceutical and Adimab to share development risks and resources.
The biotechnology sector is characterized by high capital intensity and long regulatory lead times, where clinical trial outcomes serve as primary catalysts for valuation shifts. Cullinans recent rebranding from Cullinan Oncology reflects a strategic expansion into the immunology space, diversifying its clinical risk across multiple therapeutic areas. For a more granular look at the companys financial health and valuation metrics, consider reviewing the data on ValueRay.
Headquartered in Cambridge, Massachusetts, the company maintains a portfolio that targets specific genetic mutations and cell surface proteins. This precision medicine approach aims to improve efficacy while reducing off-target toxicity compared to traditional systemic treatments.
- CLN-978 clinical trial data determines entry into high-growth autoimmune disease markets
- Zipalertinib Phase 2b results drive regulatory path for lung cancer approval
- Strategic expansion into immunology shifts valuation beyond traditional oncology assets
- Partnership milestones with Taiho Pharmaceutical impact near-term cash flow and R&D funding
- Success of bispecific T-cell engager platform dictates long-term pipeline scalability
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.44 > 0.02 and ΔFCF/TA -18.43 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.44 > 3% & CFO -178.6m > Net Income -221.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.2m) vs 12m ago 0.50% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.81 (Total Current Assets 361.4m - Total Current Liabilities 35.2m) / Total Assets 403.0m |
| B: -1.58 (Retained Earnings -637.8m / Total Assets 403.0m) |
| C: -0.45 (EBIT TTM -221.0m / Avg Total Assets 491.3m) |
| D: 9.95 (Book Value of Equity 366.2m / Total Liabilities 36.8m) |
| Altman-Z'' = 7.57 = AAA |
As of June 21, 2026, the stock is trading at USD 15.03 with a total of 3,117,300 shares traded.
Over the past week, the price has changed by +15.79%,
over one month by +6.03%,
over three months by +14.91% and
over the past year by +95.96%.
Cullinan Oncology has received a consensus analysts rating of 4.89. Therefore, it is recommended to buy CGEM.
- StrongBuy: 8
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.6 | 109.9% |
P/E Forward = 6.7385
P/S = 25.8559
P/B = 2.2952
Revenue TTM = 0.0 USD
EBIT TTM = -221.0m USD
EBITDA TTM = -220.7m USD
Long Term Debt = 1.66m USD (estimated: total debt 2.38m - short term 725k)
Short Term Debt = 725k USD (from shortTermDebt, last quarter)
Debt = 2.38m USD (from shortLongTermDebtTotal, last quarter) (leases 2.38m already included)
Net Debt = -349.5m USD (calculated: Debt 2.38m - CCE 351.9m)
Enterprise Value = 488.2m USD (837.7m + Debt 2.38m - CCE 351.9m)
Interest Coverage Ratio = unknown (Ebit TTM -221.0m / Interest Expense TTM 0.0)
EV/FCF = -2.73x (Enterprise Value 488.2m / FCF TTM -178.7m)
FCF Yield = -36.60% (FCF TTM -178.7m / Enterprise Value 488.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 311k) / Revenue TTM)
Tobins Q-Ratio = 1.21 (Enterprise Value 488.2m / Total Assets 403.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.38m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -174.6m (EBIT -221.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.28 (Total Current Assets 361.4m / Total Current Liabilities 35.2m)
Debt / Equity = 0.01 (Debt 2.38m / totalStockholderEquity, last quarter 366.2m)
Debt / EBITDA = 1.58 (negative EBITDA) (Net Debt -349.5m / EBITDA -220.7m)
Debt / FCF = 1.96 (negative FCF - burning cash) (Net Debt -349.5m / FCF TTM -178.7m)
Total Stockholder Equity = 429.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.99% (Net Income -221.0m / Total Assets 403.0m)
RoE = -51.45% (Net Income TTM -221.0m / Total Stockholder Equity 429.6m)
RoCE = -51.25% (EBIT -221.0m / Capital Employed (Equity 429.6m + L.T.Debt 1.66m))
RoIC = -47.38% (negative operating profit) (NOPAT -174.6m / Invested Capital 368.6m)
WACC = 10.50% (E(837.7m)/V(840.1m) * Re(10.53%) + D(2.38m)/V(840.1m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.75 | Cagr: 15.52%
[DCF] Fair Price = unknown (Cash Flow -178.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.49 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.85 | Chg30d=+0.86% | Revisions=+50% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.86 | Chg30d=+0.71% | Revisions=+33% | Analysts=9
EPS current Year (2026-12-31): EPS=-3.00 | Chg30d=+6.60% | Revisions=+45% | GrowthEPS=+10.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.53 | Chg30d=-1.57% | Revisions=+40% | GrowthEPS=+15.7% | GrowthRev=+126.3%
[Analyst] Revisions Ratio: +50%